Commercialisation director joins Edinburgh BioQuarter

Life sciences entrepreneur Michael Capaldi joins Scotland\'s flagship project

Michael Capaldi, scientist and life sciences entrepreneur, has been named as director of commercialisation for the Edinburgh BioQuarter – Scotland’s flagship project for the life sciences sector.

Capaldi will lead a team of up to 15 people to progress a £12m commercialisation project that will bridge the gap between industry and research.

Capaldi has more than 26 years’ experience in the pharmaceutical and life sciences industries within the UK, Europe and the US.

You may also like

Research & Development

University of Edinburgh to collaborate with Galapagos on cancer therapies

Two-year partnership with plans to extend
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Subscribe now